Verrica Pharmaceuticals Inc. Income Statement
VRCA|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Verrica Pharmaceuticals Inc. reported $8M in revenue and $77M in net loss for FY2025. Revenue has declined at a 10.9% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.6M | $5.1M | $9.0M | $12.0M | $12.0M |
| Cost of Revenue | - | $500.0K | $500.0K | - | - |
| SG&A Expense | $58.8M | $47.3M | $17.4M | $27.0M | $24.5M |
| R&D Expense | $11.8M | $4.5M | $12.2M | $15.9M | $15.7M |
| Operating Income | -$65.9M | -$65.8M | -$21.3M | -$30.9M | -$40.2M |
| Interest Expense | - | - | $2.2M | $4.3M | $3.0M |
| Income Tax | $0 | $0 | $0 | - | - |
| Net Income | -$76.6M | -$67.0M | -$24.5M | -$35.1M | -$42.7M |
| EPS (Basic) | -$14.78 | -$1.48 | -$0.72 | -$1.30 | - |
| EPS (Diluted) | -$14.78 | -$1.48 | -$0.72 | -$1.30 | -$1.71 |
| Shares Outstanding | 9.2M | 42.4M | 41.1M | 27.5M | 25.4M |
| Operating Margin | -871.3% | -1283.4% | -235.8% | -257.6% | -334.8% |
| Profit Margin | -1012.1% | -1307.5% | -271.1% | -292.3% | -355.8% |